Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
PolyPid Ltd. is a clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to prevent and treat surgical site infections (SSIs). The company operates within the biotechnology and pharmaceuticals industries, with a specific emphasis on drug-device combination products that enable controlled, localized drug delivery. PolyPid’s core value proposition is reducing post-surgical complications while limiting systemic antibiotic exposure, a key concern amid rising antimicrobial resistance.
The company’s primary product candidate is D‑PLEX100, a locally administered antibiotic formulation designed to provide sustained drug release at the surgical site. PolyPid primarily targets hospitals, surgeons, and healthcare systems involved in complex surgeries with high infection risk. Founded in 2008, the company is headquartered in Israel and has advanced its lead candidate through late-stage clinical development, culminating in a public listing on Nasdaq under the ticker PYPD in 2020.
Business Operations
PolyPid’s operations are centered on research, clinical development, and regulatory advancement of its proprietary PLEX (Polymer-Lipid Encapsulation Matrix) technology platform. The company currently operates as a single-segment business focused on developing localized anti-infective therapies, with no commercialized products as of the latest public filings. Revenue generation to date has primarily consisted of collaboration income and interest income rather than product sales.
The company conducts clinical trials internationally, including in the United States, Europe, and Israel, while relying on third-party contract research organizations and manufacturing partners. PolyPid retains full ownership of its core intellectual property and does not currently report material joint ventures or revenue-generating subsidiaries. Its operations and financial position are detailed in periodic reports filed with the U.S. Securities and Exchange Commission (SEC).
Strategic Position & Investments
PolyPid’s strategic focus is on advancing D‑PLEX100 through late-stage clinical trials for the prevention of SSIs in abdominal and colorectal surgeries, with the goal of obtaining regulatory approval in major markets. The company’s growth strategy centers on expanding indications for its PLEX platform and leveraging the same delivery technology for additional antibiotics or therapeutic agents.
The company has historically invested heavily in clinical development rather than acquisitions and does not maintain a broad portfolio of subsidiaries or external investments. Its strategy emphasizes organic development, intellectual property protection, and potential future partnerships with larger pharmaceutical or medical device companies. Data regarding additional platform candidates beyond D‑PLEX100 is limited, and broader pipeline expansion remains under evaluation based on available public disclosures.
Geographic Footprint
PolyPid is headquartered in Israel, where a significant portion of its research and development activities are based. The company also maintains a substantial operational and regulatory presence in the United States, which represents its primary target market for commercialization and clinical trials.
Clinical and regulatory activities extend across Europe, reflecting the company’s multinational trial strategy and engagement with global health authorities. While PolyPid does not operate manufacturing facilities of its own, its international footprint is supported through third-party partners and contract organizations across multiple regions.
Leadership & Governance
PolyPid was founded by Shimon Ben‑Shabat, who has played a central role in shaping the company’s strategic direction and long-term vision. The leadership team emphasizes disciplined clinical execution, regulatory rigor, and addressing unmet medical needs in surgical care.
Key members of the company’s leadership include:
- Amir Weisberg – Chief Executive Officer
- Shimon Ben‑Shabat – Founder and Chairman of the Board
Publicly available sources provide limited and occasionally inconsistent information regarding additional executive appointments. Data inconclusive based on available public sources for other named executive officers beyond those listed above.